This is a first-in-human study to learn about the study drug called BG-C9074 alone and in combination with tislelizumab in participants with advanced solid tumors.
The study drug called BG-C9075 will be given alone and in combination with tislelizumab in participants with advanced solid tumors.
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. Visit ClinicalTrials.gov to learn more about this study.
Protocol Number: 24-1128
More information available at ClinicalTrials.gov: NCT06233942
Principal Investigator